Bloomberg News

Novo Nordisk Says 2011 Sales, Profit to Be in High End of Range

October 27, 2011

Oct. 27 (Bloomberg) -- Novo Nordisk A/S, the world’s largest maker of insulin, raised its full-year outlook for revenue and profit in local currencies to the higher end of its previous forecast ranges.

Novo Nordisk expects full-year revenue growth of 10 percent to 11 percent in local currencies, compared with a previous forecast of 9 percent to 11 percent.

Novo Nordisk expects full-year revenue growth of 7.5 percent to 8.5 percent in Danish kroner, compared with a previous forecast of 6 percent to 8 percent.

Novo Nordisk expects full-year operating profit growth of 17 percent to 19 percent in local currencies, compared with a previous forecast of 15 percent to 19 percent.

Novo Nordisk expects full-year operating profit growth of 12 percent to 14 percent in Danish kroner, compared with a previous forecast of 9.5 percent to 13.5 percent.

To contact the editor responsible for this story: Christian Wienberg at cwienberg@bloomberg.net


Burger King's Young Buns
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

 
blog comments powered by Disqus